These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12005085)

  • 1. Resistance testing in children changing human immunodeficiency virus type 1 protease inhibitor.
    Servais J; Hainaut M; Schmitz V; Maes P; Fransen K; Vaira D; Brichard B; Arendt V; Schneider F; Hemmer R; Schmit JC
    Pediatr Infect Dis J; 2002 Mar; 21(3):214-20. PubMed ID: 12005085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.
    Race E; Dam E; Obry V; Paulous S; Clavel F
    AIDS; 1999 Oct; 13(15):2061-8. PubMed ID: 10546858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
    Pellegrin I; Wittkop L; Joubert LM; Neau D; Bollens D; Bonarek M; Girard PM; Fleury H; Winters B; Saux MC; Pellegrin JL; Thiébaut R; Breilh D;
    Antivir Ther; 2008; 13(2):271-9. PubMed ID: 18505178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy.
    Brindeiro PA; Brindeiro RM; Mortensen C; Hertogs K; De Vroey V; Rubini NP; Sion FS; De Sá CA; Machado DM; Succi RC; Tanuri A
    J Clin Microbiol; 2002 Dec; 40(12):4512-9. PubMed ID: 12454144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.
    Servais J; Lambert C; Fontaine E; Plesséria JM; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
    J Clin Microbiol; 2001 Feb; 39(2):454-9. PubMed ID: 11158089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
    Valer L; de Mendoza C; Soriano V
    J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal use of phenotypic resistance testing to HIV-1 protease inhibitors in patients developing HAART failure.
    Servais J; Plesséria JM; Lambert C; Fontaine E; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Schmit JC
    J Med Virol; 2002 Jul; 67(3):312-9. PubMed ID: 12116020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.
    Lorenzi P; Opravil M; Hirschel B; Chave JP; Furrer HJ; Sax H; Perneger TV; Perrin L; Kaiser L; Yerly S
    AIDS; 1999 Feb; 13(2):F17-21. PubMed ID: 10202819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
    Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
    AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
    Kaufmann GR; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper DA
    AIDS Res Hum Retroviruses; 2001 Apr; 17(6):487-97. PubMed ID: 11350662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.
    Dronda F; Casado JL; Moreno S; Hertogs K; García-Arata I; Antela A; Pérez-Elías MJ; Ruiz L; Larder B;
    AIDS Res Hum Retroviruses; 2001 Feb; 17(3):211-5. PubMed ID: 11177403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy.
    Rousseau MN; Vergne L; Montes B; Peeters M; Reynes J; Delaporte E; Segondy M
    J Acquir Immune Defic Syndr; 2001 Jan; 26(1):36-43. PubMed ID: 11176267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.
    Hertogs K; Bloor S; Kemp SD; Van den Eynde C; Alcorn TM; Pauwels R; Van Houtte M; Staszewski S; Miller V; Larder BA
    AIDS; 2000 Jun; 14(9):1203-10. PubMed ID: 10894285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
    Pellegrin I; Breilh D; Montestruc F; Caumont A; Garrigue I; Morlat P; Le Camus C; Saux MC; Fleury HJ; Pellegrin JL
    AIDS; 2002 Jul; 16(10):1331-40. PubMed ID: 12131209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.
    Zolopa AR; Shafer RW; Warford A; Montoya JG; Hsu P; Katzenstein D; Merigan TC; Efron B
    Ann Intern Med; 1999 Dec; 131(11):813-21. PubMed ID: 10610625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.
    Røge BT; Katzenstein TL; Nielsen HL; Gerstoft J
    HIV Med; 2003 Jan; 4(1):38-47. PubMed ID: 12534958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.
    Hoffmann F; Notheis G; Wintergerst U; Eberle J; Gürtler L; Belohradsky BH
    Pediatr Infect Dis J; 2000 Jan; 19(1):47-51. PubMed ID: 10643850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management].
    Manfredi R; Calza L
    Infez Med; 2002 Sep; 10(3):151-6. PubMed ID: 12704265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.